Cite
HARVARD Citation
Talayeva, S. et al. (n.d.). Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study. Breast. pp. S27-. [Online].